New weapon against tough ovarian cancer enters human testing
Disease control
Recruiting now
This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells t…
Phase: PHASE1 • Sponsor: OnCusp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC